Related references
Note: Only part of the references are listed.Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Torben Plesner et al.
BLOOD (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak et al.
BLOOD (2016)
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Christopher McCudden et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma
Judith L. Hannon et al.
TRANSFUSION (2015)
When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy
Marlies Oostendorp et al.
TRANSFUSION (2015)
Resolving the daratumumab interference with blood compatibility testing
Claudia I. Chapuy et al.
TRANSFUSION (2015)
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
S. Z. Usmani et al.
BLOOD CANCER JOURNAL (2015)
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G. Richardson et al.
LANCET HAEMATOLOGY (2015)
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
Michael Wang et al.
BLOOD (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
e-Blood Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
Richard W. J. Groen et al.
BLOOD (2012)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar et al.
BLOOD (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
Michael. S. van der Veer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Treatment of follicular non-Hodgkin's lymphoma: The old and the new
Jonathan W. Friedberg
SEMINARS IN HEMATOLOGY (2008)
Treatment of relapsed chronic lymphocytic leukemia: Old and new therapies
JC Byrd et al.
SEMINARS IN ONCOLOGY (2006)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CD38/cyclic ADP-ribose signaling: role in the regulation of calcium homeostasis in airway smooth muscle
DA Deshpande et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function
PR Kumaresan et al.
MOLECULAR IMMUNOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Human CD38: a (r)evolutionary story of enzymes and receptors
S Deaglio et al.
LEUKEMIA RESEARCH (2001)
Share Paper
